RxDoctor Payments Data

Margaret Richards, PA

Physician Assistant · Atlanta, GANPI 1699167676

Payments from drug & device makers

$7,642in general payments, 2019–2025

Across 400 payments — averaging $19.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$919
  • UCB, Inc.$703
  • Lilly USA, LLC$694
  • Biogen$626
  • AstraZeneca$532
  • Jazz Pharmaceuticals Inc.$410
  • plus $4K from 48 others

What the payments were for

  • Food & beverage$7,47498%
  • Education$1692%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,642 in reported general payments places this provider in the 95th percentile of 3,581 physician assistant providers in Georgia.

See all physician assistant providers in Georgia

Medicare billing

Part B allowed, 2024
$97,726
Medicare patients
370
Services billed
708

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate11$87,967
RytaryCarbidopa/Levodopa21$25,562
Rivastigmine60$14,442
QuliptaAtogepant12$13,417
Carbidopa-LevodopaCarbidopa/Levodopa434$11,250
Memantine Hcl425$10,038
Memantine Hcl ErMemantine Hcl145$9,374
Entacapone76$9,091
Carbidopa-Levodopa ErCarbidopa/Levodopa152$5,753
Propranolol Hcl ErPropranolol Hcl147$5,391
Gabapentin263$4,031
Donepezil Hcl513$3,791
Primidone143$3,732
AmantadineAmantadine Hcl116$3,681
Pramipexole ErPramipexole Di-Hcl11$3,039

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$73$87,96711 claims
Amneal Pharmaceuticals LLCRytary$41$25,56221 claims
AbbVieQulipta$919$13,41712 claims
Upsher-smith Laboratories LLCTopiramate$20$56175 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,581 physician assistant providers in Georgia.

Other physician assistant in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →